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Abstract
Advanced prostate cancer displays conspicuous chromosomal instability and rampant copy 
number aberrations, yet the identity of functional drivers resident in many amplicons remain 
elusive. Here, we implemented a functional genomics approach to identify new oncogenes 
involved in prostate cancer progression. Through integrated analyses of focal amplicons in large 
prostate cancer genomic and transcriptomic datasets as well as genes upregulated in metastasis, 
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276 putative oncogenes were enlisted into an in vivo gain-of-function tumorigenesis screen. 
Among the top positive hits, we conducted an in-depth functional analysis on Pygopus family 
PHD finger 2 (PYGO2), located in the amplicon at 1q21.3. PYGO2 overexpression enhances 
primary tumor growth and local invasion to draining lymph nodes. Conversely, PYGO2 depletion 
inhibits prostate cancer cell invasion in vitro and progression of primary tumor and metastasis in 
vivo. In clinical samples, PYGO2 upregulation associated with higher Gleason score and 
metastasis to lymph nodes and bone. Silencing PYGO2 expression in patient-derived xenograft 
models impairs tumor progression. Lastly, PYGO2 is necessary to enhance the transcriptional 
activation in response to ligand-induced Wnt/β-catenin signaling. Together, our results indicate 
that PYGO2 functions as a driver oncogene in the 1q21.3 amplicon and may serve as a potential 
prognostic biomarker and therapeutic target for metastatic prostate cancer.
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Introduction
Prostate cancer (PCa) is the most commonly diagnosed noncutaneous malignancy and the 
third leading cause of cancer mortality for men in the United States (1). Bone is the most 
frequent site for distant metastasis of PCa, which inflicts significant morbidity and mortality 
(2). Genomic profiling of PCa (3–7) has revealed overall lower mutation frequency 
compared with most solid cancer types (8), yet advanced disease is characterized by rampant 
genomic rearrangements and somatic copy number alterations (SCNAs) (3–7). SCNAs affect 
a larger fraction of the cancer genome than any other type of genetic alterations in cancer 
(9), underscoring the potential role of SCNAs in driving the malignant nature of PCa. 
Functional driver genes residing within recurrent amplifications include key PCa oncogenes 
such as EZH2 on 7q36.1, MYC on 8q23–24, NCOA2 on 8q13.3, and AR on Xq12 (3). Gain-
of-function screens of resident genes within amplicons is a proven approach in the 
identification of novel oncogenes.
In this study, our screen identified PYGO2 as a putative driver of PCa progression. PYGO2 
is an essential transcription co-activator with β-catenin/TCF complex for the Wnt signaling 
pathway in Drosophila (10). With a highly conserved plant homeodomain (PHD) in its C-
terminus, PYGO2 binds to H3K4me and activates β-catenin-dependent transcriptional 
regulation (11). Evidence suggests that PYGO2 modulates gene transcription through both 
Wnt-dependent and Wnt-independent mechanisms (11). Emerging data indicate its pivotal 
role in multiple cancers including glioma (12), breast cancer (13), hepatic carcinoma (14), 
and intestinal tumors (15). Recently, PYGO2 expression was identified as a potential risk 
stratification marker for PSA progression in PCa following radical prostatectomy (16). 
PYGO2 is recruited by PCGEM1, a long non-coding RNA, to enhance AR-bound enhancer 
activity (17). Nevertheless, the functional contribution of PYGO2 to PCa progression, 
particularly bone metastasis, is not known, prompting us to explore its role in PCa biology.
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Materials and Methods
Cell culture and patient-derived xenograft models
The LHMK cell line was a generous gift from William Hahn (18). LHMK and 293T 
(obtained from ATCC) were maintained in DMEM, 10% FBS. Prostate cancer cell lines 
PC-3, LNCaP, C4, C4–2, DU145 and 22Rv1 were obtained from ATCC and maintained in 
RPMI640, 10% FBS. L cells and L Wnt-3A cells were obtained from ATCC and maintained 
in DMEM, 10% FBS (for L Wnt-3A cells, 0.4 mg/ml G-418 was supplemented). ATCC 
provides the Human STR Profiling Cell Authentication Service to authenticate these cell 
lines. All cells were routinely verified as being free of mycoplasma using MycoAlert 
Mycoplasma Detection Kit (Lonza). Patient-derived xenograft (PDX) models were 
previously published and generous gifts from Dr. Nora Navone (19,20). The scramble 
control shRNA and PYGO2-targeting shRNA were ordered from Sigma, with sequences 
listed in Supplementary Table S1.
Generation of LHMK sublines for screening
The ORF lentiviral vectors in the Precision LentiORF collection were obtained from the 
Functional Genomics Facility at MD Anderson Cancer Center. In 96-well plates, we 
packaged 288 ORF lentiviruses individually and infected low-passage LHMK cells. Stable 
sublines were generated by blasticidin selection, with each sub-line individually expanded 
for the in vivo screen.
In vivo ORF screen
To evaluate the tumorigenicity of the parental cell line, LHMK cells were injected 
subcutaneously with 106 viable cells in a mixture of PBS:Matrigel (BD Biosciences) in NCr 
nude mice (Taconic), which did not form tumors 6 months post implantation. Expecting a 
small fraction of the candidate genes to promote tumorigenesis, we designed a multi-site 
subcutaneous inoculation method to reduce the number of mice needed for the screen. For 
each LHMK-ORF sub-line, 106 viable cells, resuspended in 50μL mixture of PBS:Matrigel, 
were injected subcutaneously into pre-labeled flank positions of mice (5 sites on each side of 
flank, so total 10 sites per mouse). The experiment was designed so that each subline was 
evaluated in 10 different mice, and each mouse received injections from 10 different 
sublines. Mice were monitored for tumor formation via caliper measurement for 8 months. 
We did not observed formation of more than two subcutaneous tumors on any mice in the 
screen. All animal experimental protocols were approved by the IACUC at MD Anderson 
Cancer Center.
Tissue specimens, histology and western blot
A prostate cancer tissue microarray with 80 cases and Gleason grade information was 
purchased (PR803b, US Biomax). Archived prostate cancer FFPE specimens of adjacent 
normal, primary tumor and metastasis (total n = 49) were requested from MD Anderson 
Cancer Center Prostate Cancer SPORE program (Specialized Programs of Research 
Excellence) under approved IRB protocol at MD Anderson Cancer Center. For all clinical 
samples, written informed consent was obtained from the patients. The studies were 
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conducted in accordance with recognized ethical guidelines (Declaration of Helsinki, 
CIOMS, Belmont Report, U.S. Common Rule). H&E stain, immunohistochemical (IHC) 
and western blot were performed as previously described (21). Primary antibodies used 
include PYGO2 (HPA023689, Sigma, for IHC; GTX119726, GeneTex, for western blot), 
KRAS (sc-30, Santa Cruz), FGFR1, β-Catenin, c-Myc, Met, H3K4me2, H3K4me3, H3 
(9740, 8480, 5605, 8198, 9725, 9751 and 4499, Cell Signaling Technology), β-actin 
(A2228, Sigma).
Cell proliferation and soft agar assay
For 2D proliferation, cells were seeded to 24-well plates with confluence tracked by 
IncuCyte (Essen BioScience) for 3 days. For soft agar assay, DMEM with 1% FBS, 0.6% 
LE Agarose (Lonza) was used as base layer while cells were seeded in 2×104 cells/mL in 
DMEM with 1% FBS, 0.3% SeaPlaque Agarose as top layer (Lonza). After incubated at 
37°C for 3 weeks, the colonies were stained by crystal violet and quantified.
Migration and invasion assay
Cells were first starved in DMEM with 1% FBS overnight and then seeded in serum-free 
DMEM at 5×105 cells/200μL to the chamber inserts (BD Falcon) for migration or BioCoat 
Matrigel Invasion Chamber (BD Falcon) for invasion. DMEM with 10% FBS were placed at 
the bottom as chemoattractant. Migrated or invaded cells on the membrane were stained 
with crystal violet for quantification.
Quantitative RT-PCR
RNA was isolated by RNeasy Kit (Qiagen) and reversed transcribed using Superscript III 
cDNA synthesis Kit (Life Technology). Quantitative PCR was performed using SYBR-
GreenER Kit (Life Technology). Primers are listed in Supplementary Table S1.
Functional validation using animal models
Experimental bone metastasis assay using intracardiac injection and noninvasive imaging 
was performed as previously reported (22). PDX models were passaged in the flank of 
C.B-17 SCID (Taconic) mice as previously reported (19,20). The tumors were measured by 
caliper and treated by intratumoral injection of 10μg siRNA targeting PYGO2 (Sigma-
Aldrich, SASI_HS01_00059018, or 1:1 ratio of SASI_Hs01_00059021 and 
SASI_Hs02_00363399) or control siRNA (Sigma-Aldrich, SIC001) twice a week, using 
MaxSuppressor In Vivo RNA-LANCEr II (Bioo Scientific) following the manufacturer’s 
protocol and our recent report (23).
Luciferase reporter assay
TCF/LEF reporter plasmids, M50 Super 8x TOPFlash and M51 Super 8x FOPFlash 
(TOPFlash mutant), were gifts from Randall Moon (24) (Addgene plasmid # 12456, 12457). 
Activation of Wnt/β-catenin signaling was achieved by using conditioned medium from 
Wnt3A-secreting L cells and control L cells (25). PC3 sublines were transfected with 
Lipofectamine LTX Reagent (Life Technologies) following manufacturer’s protocol and the 
reporter assay was performed as described (26).
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Statistical Analysis
Unless otherwise indicated, data represent mean ± s.d., with Student’s t-test assuming two-
tailed distributions used to calculate statistical significance between groups. P<0.05 was 
considered statistically significant (annotation: *P < 0.05, **P < 0.01, ***P < 0.001, #P > 
0.05). To display PYGO2 expression from four Oncomine transcriptomic datasets containing 
primary and metastatic PCa samples (3,4,27,28), log2 median-centered ratio of PYGO2 
probe data were drawn as Box plot with whiskers displaying 10–90 percentile using 
GraphPad Prism.
Results
In vivo ORF screen identified putative genes involved in prostate cancer progression
To enlist genes with putative function in promoting PCa progression, we performed an 
integrated oncogenomic analysis to enrich for cancer-relevant genes and cull passenger 
genes. First, genes with focal copy number gains were identified using GISTIC2 (29) from 4 
PCa genomic datasets: Taylor et al, Grasso et al, Barbieri et al, and TCGA (3–6) (Fig. 1). 
This analysis resulted in 6909 genes which were further selected based on two filters: genes 
with copy number correlated expression in at least 1 of the 4 datasets (P<0.01) and genes 
with higher expression in metastasis compared with primary tumor (P<0.05) in at least 3 out 
of 8 Oncomine transcriptomic datasets (3,4,27,30–34). The gene expression data for these 8 
datasets were directly queried from Oncomine (35). After applying the filters, 394 genes 
remained (Fig. 1). Second, to enrich for genes potentially contributing to metastasis, 363 
genes upregulated in metastasis compared with primary tumor were identified in at least 6 
out of 8 Oncomine datasets. Third, 77 amplified genes were identified from integrated 
analysis of our previous telomerase reactivation PCa mouse model and human PCa 
genomics (36). From these diverse datasets and experimental systems, a total of 741 putative 
metastasis-promoting genes were identified (Supplementary Table S2), among which 288 
ORFs (corresponding to 276 unique genes) were available at the time of experimentation 
from the Precision LentiORF Collection for lentiviral overexpression and ORF screening 
(Supplementary Table S3).
We employed LHMK cells for the in vivo screen, which were derived from primary human 
prostate epithelial cells after immortalization with SV40 LT and hTERT followed by 
transformation with MYC and PI3K (18). LHMK cells exhibit very limited tumorigenic 
capability when inoculated orthotopically or subcutaneously in nude mice (18), providing a 
suitable system to identify putative oncogenes through a gain-of-function approach. ORF-
encoded lentivirus was packaged in 96-well plates and used to transduce LHMK cells, 
followed by blasticidin selection, to establish 288 individual ORF-expressing sublines (Fig. 
2A). Overexpression of Red Fluorescent Protein (RFP) in the same LentiORF backbone was 
used as negative control (Fig. 2B). ORFs encoding KRAS and FGFR1 were used as positive 
controls (Fig. 2C), the choice of which was justified given the PCa-promoting role of RAS/
MAPK (3,37) or FGF/FGFR1 signaling, respectively (38). ORF-driven overexpression was 
validated for a number of randomly selected genes using quantitative RT-PCR 
(Supplementary Fig. S1A) which all showed various levels of overexpression of the putative 
targets. In the screen, the 288 sublines and RFP control subline were inoculated into mice 
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subcutaneously (n=10 for each ORF). Mice were monitored for tumor development for 8 
months. While no tumor growth was detected for the RFP control (total 30 sites were 
tested), the positive controls KRAS and FGFR1 generated 100% and 30% incidence of 
tumors, respectively (Supplementary Table S4). Importantly, 38 genes were identified as 
positive hits based on a 10–50% tumor incidence rate (Supplementary Table S4), among 
which 10 genes produced more than 2 tumors out of the 10 tested sites (Fig. 2D, 
Supplementary Fig. S1B). The top 10 hits include EZH2, known to be frequently 
upregulated in advanced PCa and to promote metastasis, and CCNE2 which is 
overexpressed in metastatic PCa and critical for cell cycle G1/S transition (39). Notably, the 
presence of known PCa-promoting genes among the top hits suggests the possibility that the 
other genes may represent bona fide oncogenes involved in PCa progression. To rule out the 
possibility that the negative hits were merely due to failure of LentiORF-driven gene 
overexpression, we randomly selected 26 negative hits from the lenti-ORF infected cells and 
showed that 23 out of 26 genes were upregulated more than 2-fold (Supplementary Fig. 
S1C).
Reasoning that in vitro assays could complement the in vivo result to illuminate biological 
effects, we performed proliferation, migration and invasion assays for the sublines of the top 
hits. While meager differences were observed in the two-dimensional (2D) growth curve 
assay (Fig. 3A), soft-agar assay showed that sublines overexpressing genes like KRAS, 
PYGO2, MOS, CCNE2 and MTBP could form significantly more colonies than RFP control 
(Fig. 3B). The gain of colony formation potential by genes such as PYGO2, MOS and 
MTBP (with functions in PCa uncharacterized) was accompanied by their effect on 
increased migration and invasion (Fig. 3C,D). Together, the robustness of PYGO2 in the in 
vivo ORF screen coupled with strong effect in the 3D colony assay (second only to KRAS) 
(Fig. 3B) prompted further functional investigation of this putative PCa promoting gene. 
Overexpression of BOP1 (block of proliferation 1) led to strongest enhancement of 
migration and invasion (Fig. 3C,D). Located at 8q24.3, BOP1 is close to MYC at 8q24.21. 
These two genes tend to co-amplified in the broad amplification peak at 8q24 
(Supplementary Fig. S1D), which is commonly attributed to the oncogenic function of 
MYC. Therefore, we reasoned that the amplification of BOP1 might be, at least partly, a 
passenger effect from MYC amplification, which would make a study on BOP1 less 
significant in terms of finding independent biomarker and/or therapeutic target for PCa. 
TOMM40L overexpression led to higher tumor incidence rate and shorter onset day than 
PYGO2 (Fig. 2D). The function of TOMM40L was not studied before. The commercially 
available reagents for TOMM40L are limited, making it difficult to perform clinical 
characterization of its expression and related functional studies.
PYGO2 expression is correlated with higher Gleason score and bone metastasis
PYGO2 resides on cytoband 1q21.3, a region amplified in advanced PCa (3,40,41) but 
containing no known definitive PCa oncogenes. When surveyed through PCa databases in 
cBioPortal, the status of PYGO2 copy number was retrieved from 7 studies (3,4,6,7,42–44) 
and showed higher gain or amplification in primary CRPC (53.6–76.9%) or metastasis 
CRPC (33.3–67.7%) compared with treatment-naïve primary PCa (2.7–8.7%, Fig. 4A). In 
the TCGA dataset, PYGO2 gain/amplification is associated with higher Gleason score in 
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treatment-naïve primary PCa (Fig. 4B), as well as shorter disease-free survival and shorter 
biochemical recurrence (Fig. 4C). Copy number correlated expression of PYGO2 is evident 
across several datasets (Supplementary Fig. S2A). Regarding metastasis, PYGO2 is 
significantly upregulated at the transcriptional level in metastatic PCa compared with 
primary tumors (Fig. 4D). At the protein level, tissue microarray (TMA) analysis showed 
that, while PYGO2 expression was not detectable in normal prostate, stronger PYGO2 
expression was correlated with higher Gleason score (Fig. 4E). Furthermore, from an 
archived clinical PCa sample cohort at MD Anderson Cancer Center which includes normal, 
primary tumors, lymph node metastases and bone metastases, IHC analysis showed that 
PYGO2 expression was highly upregulated in metastases (Fig. 4F). The clinical expression 
analysis, in addition to the in vivo functional screen and in vitro functional validation, 
strongly support a direct role of PYGO2 in promoting PCa progression.
PYGO2 overexpression promotes prostate tumor growth and invasion to lymph nodes
To determine if PYGO2 upregulation enhances PCa progression, we first re-tested the 
LHMK sublines expressing RFP or PYGO2 by subcutaneous inoculation in NSG mice. The 
LHMK-PYGO2 subline formed significantly larger tumors as compared to RFP controls 
(Fig. 5A, Supplementary Fig. S2B). To test the pro-tumor function of PYGO2 in a different 
PCa cell line, we overexpressed PYGO2 in LNCaP, which also has a low endogenous level 
of PYGO2 (Fig. 5B). Compared with GFP control, PYGO2 overexpression led to significant 
increase of subcutaneous tumor weight (Fig. 5B). Based on the IRES-GFP cassette in the 
overexpression vector, we identified GFP+ tumor cells in draining lymph nodes in 3 out of 
10 mice inoculated with LNCaP-PYGO2 cells (Fig. 5C, Supplementary Fig. S2C). Thus, 
PYGO2 overexpression promotes both primary tumor growth and regional lymph node 
invasion.
PYGO2 depletion inhibits prostate cancer metastasis and PDX tumor growth
To determine whether PYGO2 is required for PCa progression, we used two independent 
PYGO2 shRNA vectors to deplete PYGO2 levels in the aggressive PCa cell line PC3 (45) 
(Fig. 6A). PYGO2 knockdown resulted in modest decrease in cell proliferation in vitro 
(Supplementary Fig. S3A) but significant reduction of cell invasion (Supplementary Fig. 
S3B). When inoculated subcutaneously in mice, PYGO2 knockdown cells showed reduced 
tumorigenic potential (Fig. 6B). To evaluate whether PYGO2 knockdown affects 
spontaneous metastasis of PC3 to lung, we removed the subcutaneous tumors at Day 50 
post-inoculation and assessed metastasis formation in lung 2 months later by gross 
inspection and histology. While 60% of mice previously inoculated with the PC3-shControl 
subline developed spontaneous lung metastasis nodules, less than 20% of mice inoculated 
with the shPYGO sublines of PC3 developed lung metastasis nodules (Fig. 6C, 
Supplementary Fig. S3C). Expression of PYGO2 in PC3 cells remains pronounced in lung 
metastasis (Supplementary Fig. S3D).
As bone is the most frequent site of distant metastasis of PCa, we performed intracardiac 
injection to compare the bone colonization capability of shControl and shPYGO2 sublines 
of PC3 after labeling PC3 with a triple reporter (TR) containing firefly luciferase, GFP and 
thymidine kinase (46). Noninvasive bioluminescence imaging revealed that PYGO2 
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knockdown impaired the ability of PC3-TR cells to colonize the bone and form osteolytic 
lesions (Fig. 6D–F). PYGO2 is also expressed by a few other PCa cell lines, including 
22Rv1, C4 and C4–2 (Supplementary Fig. S3E).
As PDX models more closely resemble the clinical disease, we examined the effect of 
targeting PYGO2 in two PDX models: MDA-PCa-180 (derived from primary CRPC) (19) 
and MDA-PCa-118b (derived from bone metastatic CRPC) (20). We first performed IHC for 
PYGO2 and detected high PYGO2 expression in both models (Fig. 7A). Through 
intratumoral infusion of siRNA (either scramble control or PYGO2-targeting), we were able 
to significantly attenuate PYGO2 protein level (Fig. 7B). In both models, PYGO2-targeting 
siRNA treatment inhibited subcutaneous PDX tumor growth (Fig. 7C). For MDA-PCa-180, 
we also demonstrated the anti-tumor effect by an independent siRNA mixture 
(Supplementary Fig. S3F). Spontaneous metastasis to lung or bone from the PDX tumors 
was not detected based on histological evaluation, and metastasis was not reported to occur 
in these two models previously (19,20). These results support PYGO2 as a therapeutic target 
for PCa.
To explore the function of PYGO2 as a co-activator of the Wnt/β-catenin pathway in the 
context of PCa, we compared the ability of PC3-shControl and PC3-shPYGO2 sublines to 
activate the Wnt/β-catenin reporter TOPFlash (24) under conditioned medium from L 
Wnt-3A cells (25). As control, FOPFlash and conditioned medium from L cells were used. 
Interestingly, PYGO2 knockdown significantly reduced the Wnt-3A-induced TOPFlash 
activity (Fig. 7D). At the protein level, PYGO2 knockdown moderately decreased 
expression of β-catenin and Wnt/β-catenin targets c-Myc and Met (Fig. 7E). PYGO2 
knockdown affected little on H3K4me2 and H3K4me3 levels (Fig. 7E). Our results on the 
connection of PYGO2 with Wnt signaling was supported by the gene set enrichment 
analysis (GSEA) showing that Wnt pathway is enriched in both localized PCa and CRPC 
samples with high PYGO2 expression phenotype (Fig. 7F).
Discussion
In summary, through functional screen and analysis of recurrently amplified genes in PCa, 
we identified PYGO2 as a PCa-promoting gene capable of driving disease progression and 
metastasis. Another candidate PCa gene located on 1q21.3, CREB3L4 (a.k.a. AIbZIP, an 
androgen-regulated gene), has been reported as highly expressed in PCa (47). However, 
CREB3L4 is distinct in that its expression is neither correlated with copy number gain (3) 
nor upregulated in metastatic PCa when we surveyed the 8 Oncomine datasets (P>0.5 for all 
datasets). In fact, CREB3L4 was not among the 60 of 178 genes located in 1q21.2-q22 with 
transcript levels correlated with copy number gain (3). From the 60 genes in 1q21.2-q22, 13 
genes passed our gene selection filters and 6 genes (ENSA, LYSMD1, RPRD2, FLAD1, 
KRTCAP2, and PYGO2) were screened with available lentiviral ORFs. Only PYGO2 
emerged as a functional hit in our tumor models. Our results indicate that PYGO2 promotes 
primary tumor growth, lymph node invasion and bone metastasis. Together, we conclude 
that PYGO2 is a key driver gene of 1q21.3 that is targeted for increased expression via copy 
number gain in PCa.
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Hyperactivated Wnt signaling pathway has been increasingly identified to play important 
roles in promoting advanced prostate cancer, including the metastatic process and 
development of castration-resistant prostate cancer (48). Therefore, the implication of 
PYGO2 in Wnt pathway has significant clinical relevance. Future studies to investigate the 
molecular mechanism of PYGO2 in PCa progression will provide new opportunities to 
target lethal PCa. We envision at least two potential approaches to target PYGO2. First, the 
PHD finger in PYGO2 is responsible for binding to di- and trimethylated lysine 4 of histone 
H3 (H3K4me2/3). Therefore, small molecule inhibitors blocking the PHD finger (49) may 
serve as useful agents for PYGO2-overexpressed lethal PCa. Second, siRNAs that 
effectively downregulate PYGO2 in vivo may provide another avenue. siRNA or shRNA as 
therapeutics is being actively developed, although challenges remain in the delivery of these 
agents. That said, recent progress using exosomes to deliver siRNA or shRNA in vivo (50) 
marks a new direction for moving this idea forward.
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Figure 1. Oncogenomics-informed in vivo ORF screen.
Three sources of candidate PCa genes are integrated: 394 genes located in focal amplicons 
(4 genomics datasets) and expressed in correlation with copy number gain and metastasis 
phenotype (3/8 transcriptomic datasets); 363 genes upregulated in metastasis (6/8 
transcriptomic datasets), and 77 genes from our published cross-species PCa genome 
analysis (36). Among the total 741 candidate genes, 288 ORFs corresponding to 276 genes 
were available for screening.
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Figure 2. In vivo ORF screen identified genes promoting prostate tumorigenesis.
A, Procedure for lentivirus packaging, ORF stable overexpression in LHMK and in vivo 
tumorigenesis screen. B, Images of LHMK overexpressing the control vector RFP-IRES-
turboGFPnuc. Scale bar, 50μm. C, ORF-driven KRAS or FGFR1 overexpression in LHMK, 
confirmed with western blot. D, Top hits with 20% or higher incidence rate from the in vivo 
screen.
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Figure 3. Candidate PCa genes promote soft agar colony formation, migration and invasion.
A, Normalized confluence curves on 2D culture for selected top hit genes showing modest 
change of cell proliferation. B, Significant increase of colony formation on soft agar by 
selected top hit genes compared with RFP control. C, Significant increase of cell migration 
by selected top hit genes compared with RFP control. D, Significant increase of cell invasion 
by selected top hit genes compared with RFP control. Representative images of invaded cells 
are shown.
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Figure 4. PYGO2 is amplified in PCa and correlates with higher Gleason score and metastasis.
A, Frequency of PYGO2 copy number gain and amplification in a variety of PCa genomics 
datasets categorized by disease site and treatment. B, Fraction of PYGO2 copy number 
status in different Gleason score categories in the TCGA dataset. C, Correlation of PYGO2 
copy number status with disease-free survival (n=329) or biochemical recurrence (n=281) in 
the TCGA dataset. D, PYGO2 mRNA expression level in primary tumor and metastasis in 4 
PCa studies with data compiled from Oncomine. E, In the TMA, PYGO2 expression as 
measured by immunohistochemistry and plotted against Gleason grade categories. F, In an 
archived PCa clinical cohort from MD Anderson Cancer Center, PYGO2 expression plotted 
against categories as normal prostate, primary prostate tumor, lymph node (LN) metastases 
and bone metastases.
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Figure 5. PYGO2 overexpression promotes PCa tumor growth and invasion to draining lymph 
nodes.
A, PYGO2 overexpression in LHMK cells significantly increased subcutaneous tumor 
growth in mice (n=4). B, PYGO2 overexpression in LNCaP significantly increased 
subcutaneous tumor growth in mice (n=10). C, Summary of tumor incidence by LNCaP 
sublines and fluorescence imaging showing the invasion of LNCaP-PYGO2-IRES-GFP 
from subcutaneous tumor to local draining lymph node. In (A) and (B), *P < 0.05, **P < 
0.01, Mann-Whitney test.
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Figure 6. PYGO2 silencing reduces primary tumorigenicity and metastatic potential of PC3 cells.
A, PYGO2 knockdown by two independent shRNA clones in PC3 shown by western blot. B, 
Significant decrease of subcutaneous tumor size by PYGO2 knockdown in PC3 (n=25 for 
each group). Data represent mean ± SEM. C, Incidence of spontaneous lung metastasis from 
subcutaneous tumors formed by PC3 sublines (n=15 for each group). *P < 0.05, **P < 0.01, 
Fisher’s exact test. D,E, Weakened bone colonization ability by PYGO2 knockdown in PC3-
TR cells, shown by both bioluminescence signals (D, normalized to Day 0) and 
representative images (E, n=7 for each group). Data represent mean ± SEM. F, Osteolysis in 
the long bones induced by PC3-TR sublines, shown by X-ray radiographs and H&E 
staining. Scale bar, 500μm.
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Figure 7. Intratumoral infusion of PYGO2 siRNA blocks prostate tumor growth in PDX models.
A, Strong nuclear expression of PYGO2 in two PDX models of CRPC, detected by IHC. 
Scale bar, 100μm. B, Reduction of PYGO2 level in two PDX models by PYGO2-targeting 
siRNA, detected by western blot. C, PYGO2-targeting siRNA (Sigma-Aldrich, 
SASI_HS01_00059018) impaired PDX tumor growth. Arrows indicate the start day for 
intratumoral siRNA infusion. D, Luciferase assay measuring effect of PYGO2 knockdown 
in PC3 on the response to Wnt-3A-mediated TOPFlash reporter activity. E, Effect of 
PYGO2 knockdown in PC3 on the expression of indicated proteins, detected by western 
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blot. F, GSEA analysis for transcriptomic samples. Samples from Grasso et al. (4), 
dichotomized by normalized expression level of the PYGO2 probe A_23_P411953. KEGG 
Wnt pathway with 138 genes was the gene set for the analysis. Localized PCa and CRPC 
samples were analyzed separately, with FDR q-value being 0.051 and 0.070, respectively. 
Both FDR q-values are <0.25, the recommended FDR cutoff value by the GSEA User 
Guide.
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